Welcome to the Website ofThe VIA Consortium

The Vaccination in Atherosclerosis (VIA) program is specifically focused on developing a vaccine to protect against atherosclerosis, the primary cause of cardiovascular diseases such as heart attacks and strokes.

To be able to achieve this goal, we have assembled an extraordinary team of experts from academic research institutions, SMEs, and industry. Each of the partners brings unique capabilities to the program that cover the entire spectrum of activities from basic research and discovery, to initial preclinical development, advanced animal models of human diseases, clinical vaccine development, formulation science, adjuvant selection, and conducting clinical trials. This breadth and depth of expertise ensure that, as a team, the VIA program is able to bring the most promising product candidate(s) from the laboratory into the clinic and ultimately to patients with unmet needs.

 
 

Academic Partners

The academic partners of the VIA consortium have been selected to provide expertise that spans the many different dimensions of the development of athero-protective vaccines. All have preclinical and/or clinical experience in the development of such vaccines. The academic partners bring to this uniquely diverse consortium their own different insights on how best to address a single common target area: the role of the inflammatory-immunomodulatory pathways in atherosclerosis. They all share a common interest in modifying the immune response towards LDL or modified LDL. Academic partners have played a major role in describing the autoimmune component in atherosclerosis and identifying the role of B and T cell responses towards LDL. Therefore, the VIA consortium has chosen to focus on LDL as an antigen causing atherosclerosis and aims to develop a vaccine based on antigens or epitopes present in (modified) LDL.

SME and Industrial Partners

The SME and industrial partners of the VIA consortium provide matching expertise to their academic counterparts in establishing state-of-the-art animal models, the selection of adjuvants for vaccine development, ex vivo testing of immune responses, advanced models for the human immune system, designing of clinical trials for new treatments, and conducting First-in-Humans studies to support the registration of new therapeutic vaccines. SME and industrial partners have extensive experience in the areas necessary for vaccine development and are experienced in cooperative studies with academic partners as well as larger industry leaders in field of pharmaceutics.

 

Events & Meetings

October 2014 Meeting

VIA Consortium meeting | October 2016

When:

24 October 2016 – 26 October 2016

Where:

Hôtel Ronceray Paris Opéra, PARIS, FRANCE

The next VIA consortium meeting has been scheduled for 24th – 26th of October 2016 and will take place at the Hôtel Ronceray Paris Opéra (10 Boulevard Montmartre 75009, PARIS, FRANCE). It is located in the heart of Paris (map), within the typical Parisian "Passage Jouffroy" and close to most of the main cultural sites of Paris.

Registration: registration for the meeting is open via the following link. The password for the registration is provided by email.

Travel instructions: Access from Charles de Gaulle airport

Closest METRO station: LES GRANDS BOULEVARDS lines 8 and 9 Exit N° 2 "Musée Grévin" BUS lines that stop closely : 20, 85, 67, 74, 39,48

Agenda: please find the preliminary agenda here (coming soon). In addition to the preparation requested for the presentations during the consortium meeting, we would kindly like to ask you to update a short summary (½ to 1 A4) of your activities per WP on paper. During the consortium meeting we would like you to focus on the deliverables and milestones due at M36. However, preparation and activities of the deliverables and milestones scheduled later in the project shall also be discussed.

October 2014 Meeting

VIA Consortium meeting | JAnuary 2016

When:

18 January 2016 - 20 January 2016

Where:

Trolleholm Castle, Sweden

The next VIA consortium meeting has been scheduled for 18th – 20th of January 2016, in Trolleholm Castle Svalöv Municipality, Scania, in southern Sweden.

Registration: registration for the meeting is open via the following link . The password for the registration is provided by email.

Travel instructions: please download the pdf here.

Agenda: please find the preliminary agenda here. In addition to the preparation requested for the presentations during the consortium meeting, we would kindly like to ask you to update a short summary (½ to 1 A4) of your activities per WP on paper. During the consortium meeting we would like you to focus on the deliverables and milestones due in the next year. However, preparation and activities of the deliverables and milestones scheduled later in the project shall also be discussed.

October 2014 Meeting

VIA Consortium meeting

When:

13 October 2014 - 14 October 2014

Where:

Oegstgeest, The Netherlands

This meeting is held to evaluate the progress made in the last 9 months and to make plans for the next 6 months. Every partner is asked to prepare a presentation on their contribution to VIA over the last months. In order to align all contributions the WP leads are asked to present the contributions in a coherent way towards the objectives.

October 2014 Meeting

VIA Kick-off meeting

When:

03 February 2014 - 04 February 2014

Where:

Hortus Botanicus Leiden, The Netherlands

Overview of VIA project: brief history, objectives, expected impacts, duration, budget, time lines, main deliverables. Presentation on administrative/legal and financial issues and reports to EU commission. Partner presentations: contribution of the partner to the consortium.

 

VIA Members & Partners

BRENNTAG Nordic

Brenntag Biosector is the world leading producer of vaccine adjuvants for use in commercial vaccine production, both vaccines for human and veterinary application. The company has had its adjuvant activity since 1939.

CARDIOVAX

CardioVax is a Los Angeles based biotechnology company focusing on immunotherapies for cardiovascular disease. The company has evolved from innovative discoveries at the Lund University Hospital in Malmö and Cedars-Sinai Medical Center.

CHDR

CHDR is specialized in first-in-humans and proof-of concept studies. P10 has access to CVD patients in cooperation with several University Medical Centres in The Netherlands and the intended clinical trial. P10 can perform studies in healthy volunteers as well as a second phase trial focused on determining effectiveness in CVD patients.

INSERM

INSERM (Institut National de la Santé et de la Recherche Médicale) is the French public organisation dedicated to biological, medical and public health research. U 698 (www.insermU698.fr) is part of the INSERM and is affiliated to the University of Paris 7. It is located within the campus of the University hospital Bichat in Paris, one of the reference care centers for cardiovascular disease in France.

Karolinska Institutet

Karolinska Institutet is a medical university in Solna within the Stockholm urban area, Sweden, and one of Europe's largest and most prestigious medical universities. It was founded in 1810, and is Sweden's third oldest medical school, after Uppsala University (founded in 1477) and Lund University (founded in 1666). Research at Karolinska Institute accounts for more than 40% of all academic medical research in Sweden. Karolinska Institute consistently ranks among the top universities in the world.

 Leiden University

The VIA researchers all work within the Division of Biopharmaceutics of the Leiden Academic Centre for Drug Research (LACDR) within the Science faculty of Leiden University. The Science Faculty with its current focus on "The Science Base of Health" is centered on developing drug therapies for diseases in the field of cancer and cardiovascular disease and is therefore intensively collaborating with the Leiden University Medical Centre.

Lund University

Lund University is the largest and highest ranked full-scale university in Scandinavia. Its medical faculty offers a wide range of research, from experimental to applied. The VIA researchers all work within the Department of Clinical Sciences in Malmö.

University of Vienna

The Medical University of Vienna is Austria's largest medical training center and one of Europe's leading medical universities. Clinical Departments and Research Centers are located at the General Hospital of Vienna (AKH), one of the largest hospitals in Europe. Researchers involved in the VIA network will work in the research facilities of the Department of Laboratory Medicine as well as the Research Centre for Molecular Medicine of the Austrian Academy of Sciences.

PolyGene

PolyGene was founded in 2001 with a unique and novel transgenesis technology aimed at reducing the number of animals needed for biological experimentation by providing novel models and thereby reducing the number of strains necessary within the investigation of a given project.

ProBioGen

ProBioGen AG is a service and technology provider for animal cell-based biopharmaceuticals, from recombinant high-producer cell lines up to GMP manufacturing of therapeutic proteins and including sophisticated cell-based analytical assays. One of the proprietary platform technologies which ProBioGen has developed is the human Artificial Lymph Node (HuALN) model, created to assess drug-related effects on the human immune system in vitro.

University of Cambridge

The University of Cambridge is one of the world's oldest universities and leading academic centres. The mission of the University is to contribute to society through the pursuit of education, learning, and research at the highest international levels of excellence. The VIA researchers all work within the Department of Medicine.

University of Gothenburg

The University of Gothenburg is one of the largest universities in Scandinavia. Its health faculty The Sahlgrenska Academy offers a wide range of research, from experimental to applied. One of its areas of international strength is in the field of vaccines and related immunology, especially mucosal vaccines, for which it has a specific research facility (GUVAX).

Cardiovascular Disease

Cardiovascular disease (CVD) is still a leading cause of death in the European Union (EU) accounting for nearly half of all deaths in Europe (48%). In addition, CVD complications lead to a vast number of hospitalizations and thus to a great burden of health care costs in the EU. Atherosclerosis and its final complication, plaque rupture and subsequent infarct in heart or brain, is the main underlying pathology of CVD and atherosclerosis is responsible for 70% of all cases of CVD.

Atherosclerosis

Extensive studies into the pathology of atherosclerosis show that its etiology is found in a combination of dyslipidemia and a related inflammatory response with an established autoimmune component, while the major cause of acute CVD events, plaque rupture, due to an inflammatory destabilization of the atherosclerotic lesion. CVD is therefore an autoimmune-like disease in the context of a metabolic disease. Thus far, therapeutic approaches in CVD have been focused at normalizing dyslipidemia in order to lower plasma cholesterol. Statins and additional surgical approaches such as angioplasty have achieved a 30% risk reduction for CVD during the last 10-15 years. However, additional approaches to improve the treatment of dyslipidemia by for instance improving the level of the anti-atherogenic lipoprotein HDL have failed in a number of clinical trials. This implicates that new therapeutic approaches are urgently needed to narrow down the remaining 70% risk for CVD. We aim to develop a new immunomodulatory treatment, a therapeutic vaccine that permanently restores the immune balance within the arterial wall by inhibiting the inflammatory responses during atherosclerosis. The VIA consortium aims to develop a vaccine, dissect the immune pathways underlying the beneficial effect of the vaccine, optimize the vaccine, test its safety and perform a phase I clinical trial using the atheroprotective vaccine. The vaccine is foreseen to result in a substantial lowering of the risk for CVD.

EU Health Research

The objective of the health research programme is to improve the health of European citizens, and increase and strengthen the competitiveness and innovative capacity of European health-related industries and businesses. Global health issues, like emerging epidemics, will also be addressed. European collaboration with developing countries will allow those countries to develop research capacities.

VIA - Vaccination In Atherosclerosis

Time period: 2013-12-01 - 2018-11-30

Instrument: Collaborative project

Call: FP7-HEALTH-2013-INNOVATION

Principal investigators

Scientific co-ordinator: Johan Kuiper (UNIVERSITEIT LEIDEN.)

Other principal investigators: Jan Nilsson (LUNDS UNIVERSITET), Göran Hansson (KAROLINSKA INSTITUTET), Christoph Binder (MEDIZINISCHE UNIVERSITAET WIEN), Jan Holmgren (GOETEBORGS UNIVERSITET), Giuseppina Caligiuri (INSERM - Institut national de la santé et de la recherche médicale), Ziad Mallat (THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE), Stefan Selbert (POLYGENE AG), Mark Carvlin (CARDIOVAX LLC), Koos Burggraaf (STICHTING CENTRE FOR HUMAN DRUG RESEARCH), Erik Lindblad (BRENNTAG NORDIC AS/BRENNTAG BIOSECTOR AS), Christoph Giese (PROBIOGEN AG)

Top